EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer

Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR TKIs) greatly improved clinical outcomes of patients with non-small cell lung cancer (NSCLC). Unfortunately, primary and acquired resistance limits their clinical benefits. To overcome such resistance, new generations of EGFR TKIs...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Signal Transduct Target Ther
Main Authors: Yang, Lixian, Ying, Shilong, Hu, Shiman, Zhao, Xiangtong, Li, Muchun, Chen, Miaoqin, Zhu, Yiran, Song, Ping, Zhu, Liyuan, Jiang, Tingting, An, Huimin, Yousafzai, Neelum Aziz, Xu, Wenxia, Zhang, Zhiguo, Wang, Xian, Feng, Lifeng, Jin, Hongchuan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6799834/
https://ncbi.nlm.nih.gov/pubmed/31637005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-019-0059-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados